Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
暂无分享,去创建一个
J. Czernin | K. Herrmann | K. Nguyen | M. Eiber | W. Fendler | J. Calais | J. Gartmann | R. Slavik | Magnus Dahlbom | V. Lok | Laura Gosa | W. Armstrong | P. Thin